|
- I tried Stdei GLP-1 Oral Drops: here’s my BRUTAL review
Stdei GLP-1 Oral Slimming Drops are just another scammy product taking advantage of moms like us who are trying to reclaim their bodies while managing busy family life I wanted to believe it might work, but it’s right up there with the other social media diet fads I’ve tested
- Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health . . .
A recent study published in Nature Medicine may provide valuable insights into the previously unreported benefits and risks of glucagon-like peptide-1 (GLP-1) receptor agonist use on a set of 175 health outcomes
- Lillys oral GLP-1, orforglipron, showed compelling efficacy and a . . .
"The ACHIEVE-1 trial demonstrated that orforglipron, a novel oral small-molecule GLP-1, achieved clinically meaningful reductions in A1C and body weight over 40 weeks in adults with type 2 diabetes," said Dr Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults
- Oral GLP-1 Medications: A Convenient Solution for Long-Term Weight Loss
Oral GLP-1 medications offer a super convenient and effective option for long-term weight loss, especially for those who’ve struggled with traditional methods They help curb your appetite, keep you feeling fuller longer, and can even improve your blood sugar levels
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Clinical trial and real-world data suggest that GLP-1RA exert an additive cardiovascular benefit when used concomitantly with sodium–glucose cotransporter 2 inhibitors (SGLT2i) to treat people with type 2 diabetes (14–17)
- Oral GLP-1 Receptor Agonists for Weight Loss - PubMed
Herein, we review the current literature regarding the use of oral GLP-1 receptor agonists specifically for obesity including semaglutide, danuglipron, and orforglipron, with a focus on oral semaglutide as it is Food and Drug Administration-approved, although not for obesity alone
- GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity
Ascletis announces positive interim results from first 2 cohorts of US phase Ib multiple ascending dose study of small molecule oral GLP-1R agonist ASC30 News release Ascletis Pharma Inc February 19, 2025
|
|
|